In Animal Study, Implant Churns Out CAR-T Cells to Combat Cancer
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors. In a proof-of-concept study involving lymphoma in mice, the researchers found that treatment with the implants was faster and more effective than conventional CAR-T cell cancer treatment.
T cells are part of the immune system, tasked with identifying and destroying cells in the body that have become infected with an invading pathogen. CAR-T cells are T cells that have been engineered to identify cancer cells and destroy them. CAR-T cells are already in clinical use for treating lymphomas, and there are many clinical trials under way focused on using CAR-T cell treatments against other forms of cancer.
“A major drawback to CAR-T cell treatment is that it is tremendously expensive – hundreds of thousands of dollars per dose,” says Yevgeny Brudno, corresponding author of the study and assistant professor in the joint biomedical engineering department at NC State and UNC.
“Due to its cost, many people are shut out from this treatment. One reason for the high cost is that the manufacturing process is complex, time-consuming and has to be tailored to each cancer patient individually,” Brudno says. “We wanted to address challenges in CAR-T treatment related to both manufacturing time and cost.”
“Reducing the manufacturing time is even more critical for patients with rapidly progressing disease,” says Pritha Agarwalla, lead author of the study and a postdoctoral researcher in the joint biomedical engineering department.
To tackle this challenge, the researchers created a biotechnology called Multifunctional Alginate Scaffolds for T cell Engineering and Release (MASTER). The work was done in partnership with Gianpietro Dotti, professor in the Department of Microbiology and Immunology and co-leader of the Immunology Program at the Lineberger Cancer Center at UNC; and Frances Ligler, a professor of biomedical engineering at Texas A&M University.
To understand how MASTER works, you have to understand how CAR-T cells are produced. Clinicians first isolate T cells from patients and transport them to a clean manufacturing facility. At this facility, researchers “activate” T cells with antibodies over several days, preparing them for reprogramming. Once T cells are activated, researchers use viruses to introduce the CAR gene, reprogramming the T cells into CAR-T cells that target cancer cells. Researchers then add factors to stimulate the CAR-T cells to proliferate, expanding their number. Finally, after these manipulations are complete – a process that can take weeks – the cells are brought back to the hospital and infused into the patient’s bloodstream.
“Our MASTER technology takes the cumbersome and time-consuming activation, reprogramming and expansion steps and performs them inside the patient,” Agarwalla says. “This transforms the multi-week process into a single-day procedure.”
MASTER is a biocompatible, sponge-like material with the look and feel of a mini marshmallow. To begin treatment, researchers isolate T cells from the patient and mix these naïve (or non-activated) T cells with the engineered virus. Researchers pour this mixture on top of the MASTER, which absorbs it. MASTER is decorated with the antibodies that activate the T cells, so the cell activation process begins almost immediately. Meanwhile, MASTER is surgically implanted into the patient– in these studies, a mouse.
After implantation, the cellular activation process continues. As the T cells become activated, they begin responding to the modified viruses, which reprogram them into CAR-T cells.
“The large pores and sponge-like nature of the MASTER material brings the virus and cells close together, which facilitates cellular genetic reprogramming,” says Agarwalla.
The MASTER material is also impregnated with factors called interleukins that foster cell proliferation. After implantation, these interleukins begin to leach out, promoting rapid proliferation of the CAR-T cells.
“Engineering the material so that it is dry and absorbs this combination of T cells and virus is critically important,” Brudno says. “If you try to do this by applying T cells and virus to a wet MASTER, it just doesn’t work.”
In these studies, the researchers worked with mice that had lymphoma. One group was treated with CAR-T cells that were created and delivered using MASTER. A second group was treated with CAR-T cells that were created conventionally and delivered intravenously. These two groups were compared to control group receiving non-engineered T cells.
“Our technology performed very well,” Brudno says. “It would take at least two weeks to create CAR-T cells from naïve T cells for clinical use. We were able to introduce the MASTER into a mouse within hours of isolating naïve T cells.”
In addition, since cells are implanted within hours of isolation, the minimal manipulation creates healthier cells that exhibit fewer markers associated with poor anti-cancer performance in CAR-T cells. Specifically, the MASTER technique results in cells that are less differentiated, which translates to better sustainability in the body and more anti-cancer potency. In addition, the cells display fewer markers of T-cell exhaustion, which is defined by poor T cell function.
“The end result is that the mice that received CAR-T cell treatment via MASTER were far better at fighting off tumors than mice that received conventional CAR-T cell treatment,” Agarwalla says.
The improvement in anti-cancer efficacy was especially pronounced over the long term, when mice were faced with a recurrence of lymphoma.
“The MASTER technology was very promising in liquid tumors, such as lymphomas, but we are especially eager to see how MASTER performs against solid tumors – including pancreatic cancer and brain tumors,” Brudno says.
“We’re working with an industry partner to commercialize the technology, but there’s still a lot of work to be done before it becomes clinically available. Further work to establish the safety and robustness of this technology in animal models will be necessary before we can begin exploring clinical trials involving human patients.”
While it’s impossible to estimate what the cost of MASTER treatment might be if it is eventually approved for clinical use, Brudno says he’s optimistic that it would be substantially less expensive than existing CAR-T treatment options.
“We’re also exploring opportunities with other industry partners for taking the fundamental concepts of MASTER and applying them for use in regenerative medicine and in treating autoimmune disease,” Brudno says.
“I feel like we’re just scratching the surface of what’s possible here,” Agarwalla says.
The paper, “Bioinstructive Implantable Scaffolds for Rapid In Vivo Manufacture and Release of CAR-T Cells,” is published in Nature Biotechnology. The paper was co-authored by Kristen Froehlich, a former undergraduate at NC State; Edikan Ogunnaike, Sarah Ahn of UNC; and Anton Jansson of NC State.
Agarwalla, Dotti and Brudno are inventors on patents related to the use of biomaterials for generation of CAR-T cell therapeutics. Brudno has received an industry-sponsored research grant related to CAR-T cell therapeutic technology (unrelated to this work). Dotti is a paid consultant for Bellicum Pharmaceuticals, Tessa Therapeutics and Catamaran.
The work was done with support from the North Carolina Biotechnology Center, under flash grant 2019-FLG-3812; from the National Center for Advancing Translational Sciences; and from the National Institutes of Health under grants UL1TR002489, R01CA193140, R21-CA229938-01A1, T32CA196589 and R25NS094093.
Note to Editors: The study abstract follows.
“Bioinstructive Implantable Scaffolds for Rapid In Vivo Manufacture and Release of CAR-T Cells”
Authors: Pritha Agarwalla and Kristen Froehlich, Joint Biomedical Engineering Program at North Carolina State University and the University of North Carolina at Chapel Hill; Edikan A. Ogunnaike and Sarah Ahn, University of North Carolina at Chapel Hill; Anton Jansson, North Carolina State University; Frances S. Ligler, Texas A&M University; Gianpietro Dotti, University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center; Yevgeny Brudno, Joint Biomedical Engineering Program at North Carolina State University and the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center.
Published: March 24, Nature Biotechnology
Abstract: Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing procedures that might lead to cell products with heterogeneous composition. Here we describe an implantable Multifunctional Alginate Scaffold for T Cell Engineering and Release (MASTER) that streamlines in vivo CAR-T cell manufacturing and reduces processing time to a single day. When seeded with human peripheral blood mononuclear cells and CD19-encoding retroviral particles, MASTER provides the appropriate interface for viral vector-mediated gene transfer and, after subcutaneous implantation, mediates the release of functional CAR-T cells in mice. We further demonstrate that in vivo-generated CAR-T cells enter the bloodstream and control distal tumor growth in a mouse xenograft model of lymphoma, showing greater persistence than conventional CAR-T cells. MASTER promises to transform CAR-T cell therapy by fast-tracking manufacture and potentially reducing the complexity and resources needed for provision of this type of therapy.
This post was originally published in NC State News.